[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RC, Grier HE: Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol; 2002 Dec;24(9):722-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston.
  • PURPOSE: To retrospectively evaluate the treatment and outcome of patients diagnosed with infantile fibrosarcoma at the Dana-Farber Cancer Institute and Children's Hospital, Boston.
  • PATIENTS AND METHODS: Between 1982 and 1998, a total of 11 infants were diagnosed pathologically with infantile fibrosarcoma.
  • A retrospective chart review was conducted to determine the extent of surgical therapy and chemotherapy required for a favorable clinical outcome.
  • Two patients received chemotherapy only after limited biopsy or subtotal resection and are alive with no evidence of disease 8 and 18 years from diagnosis.
  • Four patients had limited biopsies followed by chemotherapy with delayed resection.
  • One of these four patients had negative margins and received no further chemotherapy.
  • The other three of these patients had positive microscopic margins; two of them received postoperative chemotherapy while the third did not.
  • Two patients had progressive disease within 7 and 10 months of diagnosis while on chemotherapy after subtotal resections.
  • Seven patients had archived or frozen tissue available for molecular analysis.
  • Six patients had characteristic trisomies previously reported to be associated with infantile fibrosarcoma.
  • CONCLUSIONS: Previously reported series of treatment outcomes in infantile fibrosarcoma have been limited to very few patients due to the rare occurrence of this tumor.
  • In our experience, initial chemotherapy combined with surgery has been successful for most cases.
  • When disease progression occurred, it was within one year of diagnosis.
  • The role of additional chemotherapy for microscopic margins after local control is not clear.
  • We found a high incidence of the TEL/TRKC fusion gene, confirming its utility in diagnosis.
  • We propose a uniform approach to treatment to gather clinical and biologic information about this rare and curable disease.
  • [MeSH-major] Fibrosarcoma / drug therapy. Fibrosarcoma / surgery
  • [MeSH-minor] Boston. Child. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Registries. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468912.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 28825; United States / NCI NIH HHS / CA / K23 CA 80915
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


2. Canale S, Vanel D, Couanet D, Patte C, Caramella C, Dromain C: Infantile fibrosarcoma: magnetic resonance imaging findings in six cases. Eur J Radiol; 2009 Oct;72(1):30-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma: magnetic resonance imaging findings in six cases.
  • PURPOSE: To retrospectively review magnetic resonance (MR) imaging features in a series of six infantile fibrosarcomas to find out if MR can suggest this unusual diagnosis and to highlight the value of MR during and following treatment.
  • MATERIALS AND METHODS: The records of six cases of histologically proven infantile fibrosarcoma were retrieved from the files of our cancer center.
  • RESULTS: There were five females and one male (age range at diagnosis, 0-12 months; mean, 6 months).
  • All tumors had arisen on limbs; at their proximal or distal extremity or at the root of the limb.
  • After treatment (chemotherapy and very limited surgery), tumors had totally disappeared, leaving muscle fat infiltration in two patients and subcutaneous fat hypertrophy in one patient.
  • CONCLUSION: Although imaging findings are not specific of infantile fibrosarcoma, this diagnosis could be suggested when MR imaging depicts a large well-circumscribed mass arising in a limb at birth or during the neonatal period.
  • MR is also the technique of choice for follow-up during treatment which consists nowadays almost exclusively in chemotherapy.
  • [MeSH-major] Fibrosarcoma / diagnosis. Fibrosarcoma / therapy. Magnetic Resonance Imaging / methods. Muscle Neoplasms / diagnosis. Muscle Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Infant. Infant, Newborn. Male. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523781.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


3. Muzaffar AR, Friedrich JB, Lu KK, Hanel DP: Infantile fibrosarcoma of the hand associated with coagulopathy. Plast Reconstr Surg; 2006 Apr 15;117(5):81e-86e
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma of the hand associated with coagulopathy.
  • BACKGROUND: Large congenital neoplasms of the extremities may be associated with coagulopathies and significant hemorrhage in the neonatal period.
  • At times, the differences between coagulation derangements can be very subtle, leading to errors in diagnosis.
  • It is important to obtain accurate diagnoses of the neoplasm and the coagulopathy because the treatments of similar-appearing tumors and coagulopathies can be markedly different.
  • METHODS: The authors report the case of a newborn with a congenital tumor of the left hand that was accompanied by a coagulopathy that caused significant bleeding.
  • However, steroid treatment did not reduce the size of the mass or correct the coagulopathy.
  • Only after obtaining consultation with a hand surgeon and a tissue diagnosis was it learned that the patient had an infantile fibrosarcoma that was accompanied by disseminated intravascular coagulation.
  • Limb-sparing resection of the lesion along with chemotherapy markedly improved the patient's condition.
  • CONCLUSIONS: Large congenital neoplasms presenting with attendant bleeding diatheses must be rapidly and accurately diagnosed with both a biopsy-proven tissue diagnosis and a hematologic characterization of the nature of the coagulopathy.
  • The differential diagnosis of a vascular-appearing mass in the extremity can be subtle, and presumptive diagnosis, as occurred in this case, can lead to incorrect or delayed treatment.
  • Specifically, kaposiform hemangioendothelioma must be differentiated from infantile fibrosarcoma.
  • The principles of infantile fibrosarcoma treatment are limb-sparing resection and chemotherapy.
  • [MeSH-major] Fibrosarcoma / congenital. Fibrosarcoma / diagnosis. Hand

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641700.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Loeb DM, Hill DA, Dome JS: Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol; 2002 Aug-Sep;24(6):478-81
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy.
  • Congenital mesoblastic nephroma (CMN) is usually cured by surgery.
  • The sensitivity of this tumor to chemotherapy is unknown.
  • The recent description of a t(12;15)(p13;q25) chromosomal translocation in both cellular CMN and congenital infantile fibrosarcoma suggests that these entities have a common pathogenesis, and that cellular CMN might respond to chemotherapy like congenital infantile fibrosarcoma does.
  • The authors describe three patients with recurrent cellular CMN who showed a complete response to chemotherapy.
  • Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nephroma, Mesoblastic / drug therapy


5. Ferguson WS: Advances in the adjuvant treatment of infantile fibrosarcoma. Expert Rev Anticancer Ther; 2003 Apr;3(2):185-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the adjuvant treatment of infantile fibrosarcoma.
  • Infantile fibrosarcoma is a rare soft tissue tumor, predominately affecting young infants.
  • Neoadjuvant chemotherapy will cause many tumors to shrink significantly, allowing less mutilating surgical resections to be performed--this is the current recommendation where immediate surgical removal cannot be accomplished without unacceptable morbidity.
  • In contrast, there is no defined role for adjuvant chemotherapy or radiation following complete surgical resection.
  • [MeSH-major] Fibrosarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Infant

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12722878.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


6. DeComas AM, Heinrich SD, Craver R: Infantile fibrosarcoma successfully treated with chemotherapy, with occurrence of calcifying aponeurotic fibroma and pleomorphic/spindled celled lipoma at the site 12 years later. J Pediatr Hematol Oncol; 2009 Jun;31(6):448-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma successfully treated with chemotherapy, with occurrence of calcifying aponeurotic fibroma and pleomorphic/spindled celled lipoma at the site 12 years later.
  • The treatment of infantile fibrosarcoma has traditionally been wide resection.
  • Chemotherapy has been investigated as an adjuvant and primary treatment in cases in which surgery would cause unacceptable morbidity.
  • Recurrences normally occur within a year of completion of the chemotherapy and display the same histology.
  • We present a child with an infantile fibrosarcoma of the elbow, successfully treated with chemotherapy alone, who developed a calcifying aponeurotic fibroma and a spindle cell/pleomorphic lipoma at the tumor site 12 years later.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fibroma / etiology. Fibrosarcoma / drug therapy. Lipoma / etiology. Neoplasms, Second Primary / etiology. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648795.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Russell H, Hicks MJ, Bertuch AA, Chintagumpala M: Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer; 2009 Jul;53(1):23-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy.
  • BACKGROUND: Infantile fibrosarcoma (IF) is a rare soft tissue sarcoma that presents either at birth or in the first year of life.
  • Complete surgical resection is usually curative but chemotherapy may shrink the tumor to facilitate complete resection.
  • This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection.
  • PROCEDURE: A retrospective review was performed of patients treated between 2000 and 2007.
  • Two lower extremity tumors had only modest changes in dimensions but upon resection, the tumor bed contained fibrous tissue with exaggerated small caliber vessels.
  • The fourth infant developed metastatic lesions in the central nervous system, orbits, lungs, and kidney after complete removal of the primary tumor.
  • The metastatic lesions responded to chemotherapy and have remained stable for over 3 years.
  • In patients where a clinical response is not apparent, cytoreduction of the tumor and replacement with fibrotic and fibrovascular tissue may facilitate gross-total resection.
  • The chemotherapy-responsiveness of this tumor may abrogate unfavorable features such as metastatic or residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Infant. Infant, Newborn. Leg. Lymphatic Metastasis. Male. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19340853.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Akyüz C, Sari N, Vargel I, Gedikoglu G, Haliloglu M, Büyükpamukçu M: A newborn with infantile fibrosarcoma of foot: treatment with chemotherapy and extremity-sparing surgery. J Perinatol; 2010 Jan;30(1):63-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A newborn with infantile fibrosarcoma of foot: treatment with chemotherapy and extremity-sparing surgery.
  • Infantile fibrosarcoma represents less than 1% of all childhood cancers, but it is the most common soft-tissue sarcoma in those under 1 year of age.
  • We report an infant with congenital infantile fibrosarcoma diagnosed as hemangiopericytoma.
  • He was treated with chemotherapy and extremity-sparing surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Fibrosarcoma / drug therapy. Fibrosarcoma / surgery. Foot Diseases / congenital. Hemangiopericytoma / drug therapy. Hemangiopericytoma / surgery

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038940.001).
  • [ISSN] 1476-5543
  • [Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association
  • [ISO-abbreviation] J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Kurkchubasche AG, Halvorson EG, Forman EN, Terek RM, Ferguson WS: The role of preoperative chemotherapy in the treatment of infantile fibrosarcoma. J Pediatr Surg; 2000 Jun;35(6):880-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of preoperative chemotherapy in the treatment of infantile fibrosarcoma.
  • Infantile fibrosarcoma (IFS) is a rare tumor most often affecting the extremities of infants and young children.
  • The dramatic response in 2 recent cases to preoperative chemotherapy, given in an attempt to avoid amputation, prompted this report and a review of the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arm. Fibrosarcoma / congenital. Fibrosarcoma / surgery
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Humans. Infant, Newborn. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873030.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  • [Number-of-references] 15
  •  go-up   go-down


10. Demir HA, Akyüz C, Varan A, Ergen FB, Büyükpamukçu M: Right foot congenital infantile fibrosarcoma treated only with chemotherapy. Pediatr Blood Cancer; 2010 Apr;54(4):618-20
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right foot congenital infantile fibrosarcoma treated only with chemotherapy.
  • Congenital infantile fibrosarcoma (CIF) is a rare tumor in childhood.
  • We report the case of a male newborn with a mass in his right foot.
  • The patient was treated only with VAC chemotherapy and is able to walk normally.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / congenital. Fibrosarcoma / drug therapy. Foot / pathology. Soft Tissue Neoplasms / congenital. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Humans. Infant, Newborn. Male. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Foot Health.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2010 Oct;55(4):770; author reply 771 [20533521.001]
  • (PMID = 19998472.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


11. Patel Y, Mitchell CD, Hitchcock RJ: Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology; 2003 Jun;61(6):1260
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
  • Congenital mesoblastic nephroma was originally considered to be a benign neoplasm.
  • A more aggressive cellular form, however, that has a close relationship to congenital fibrosarcoma, is widely described.
  • We describe a patient with isolated metastasis to liver and review the management, together with evidence that it may be more appropriate to use a vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) regimen rather than Wilm's tumor-based regimens in those cases for which chemotherapy is indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / congenital. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secretion. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / secondary. Sarcoma / drug therapy


12. McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol; 2003 May;40(5):288-92
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy.
  • BACKGROUND: Recently, the ETV6-NTRK3 gene fusion has been identified in both infantile fibrosarcoma and cellular mesoblastic nephroma.
  • For both these tumors standard curative treatment has been primarily surgical with wide local excision.
  • PROCEDURE: This report discusses three infants with congenital tumors, two congenital fibrosarcomas, and one atypical congenital mesoblastic nephroma, not easily amenable to surgical intervention.
  • RESULTS: All three were treated with pre-operative chemotherapy with excellent responses negating the need for amputation in two patients.
  • In this group of patients pre-operative chemotherapy may abrogate the need for morbid surgical procedures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / genetics. Fibrosarcoma / congenital. Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital. Receptor, trkC / genetics. Repressor Proteins / genetics. Soft Tissue Neoplasms / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12652616.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Genetic Markers; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


13. Gülhan B, Küpeli S, Yalçin B, Akyüz C, Büyükpamukçu M: An unusual presentation of infantile fibrosarcoma in a male newborn. Am J Perinatol; 2009 May;26(5):331-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of infantile fibrosarcoma in a male newborn.
  • We describe a 10-day-old male presenting with drop foot and immobility in his right leg; no abnormality in physical examination had been found upon delivery or discharge.
  • Fine-needle aspiration biopsy revealed congenital infantile fibrosarcoma.
  • He was started on vincristine, actinomycin-D, cyclophosphamide chemotherapy.
  • Differential diagnosis of drop foot and immobility in lower extremity must include infiltrating neoplasms in pelvis.
  • [MeSH-major] Fibrosarcoma / complications. Fibrosarcoma / diagnosis. Paralysis / etiology. Pelvic Neoplasms / complications. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Fatal Outcome. Hepatic Veno-Occlusive Disease / diagnosis. Hepatic Veno-Occlusive Disease / etiology. Hepatic Veno-Occlusive Disease / therapy. Hip. Humans. Infant, Newborn. Leg. Male. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067284.001).
  • [ISSN] 1098-8785
  • [Journal-full-title] American journal of perinatology
  • [ISO-abbreviation] Am J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


14. Yalçin B, Leblebicioğlu G, Güler E, Gedikoğlu G, Kutluk MT: Congenital infantile fibrosarcoma of the thigh in a newborn. Tumori; 2001 Nov-Dec;87(6):436-8
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital infantile fibrosarcoma of the thigh in a newborn.
  • Congenital/infantile fibrosarcoma occurs frequently in the first year of life and differs from fibrosarcoma in adulthood.
  • The clinical course of congenital/infantile fibrosarcoma is more favorable and metastatic spread is rare.
  • While adult fibrosarcomas are common in the thigh, congenital/infantile fibrosarcomas affect chiefly the distal portions of the extremities.
  • Standard treatment is primarily wide surgical excision.
  • Chemotherapy may be given as neoadjuvant or adjuvant treatment in order to avoid the morbidity associated with wide excision.
  • In this case report we present our experience of a newborn affected by congenital/infantile fibrosarcoma of the left thigh.
  • [MeSH-major] Fibrosarcoma / congenital. Fibrosarcoma / diagnosis. Thigh
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Humans. Infant, Newborn. Male. Neoadjuvant Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989601.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Orbach D, Rey A, Cecchetto G, Oberlin O, Casanova M, Thebaud E, Scopinaro M, Bisogno G, Carli M, Ferrari A: Infantile fibrosarcoma: management based on the European experience. J Clin Oncol; 2010 Jan 10;28(2):318-23
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma: management based on the European experience.
  • PURPOSE: To retrospectively analyze the clinical features and results of treatment in 56 infants with fibrosarcoma enrolled onto cooperative European protocols between 1979 and 2005 and treated with a combination of surgery and chemotherapy.
  • PATIENTS AND METHODS: We performed a retrospective case review of infants under the age of 2 years with fibrosarcoma treated between 1979 and 2005 in six European studies.
  • Patients were staged according to the Intergroup Rhabdomyosarcoma Staging System international classification as a function of the type of initial surgery and the extent of disease and were treated with surgery and chemotherapy.
  • Response rate to chemotherapy was 75%, and the specific response rate to vincristine-dactinomycin was 71%.
  • At the end of follow-up, 45% of survivors had been treated by surgery alone, 6% by chemotherapy alone, 46% by surgery and chemotherapy, and 2% by surgery, chemotherapy, and radiotherapy.
  • CONCLUSION: Although complete resection is rarely feasible at diagnosis, conservative surgery remains the mainstay treatment for infantile fibrosarcoma.
  • An alkylating agent-free and anthracycline-free regimen is usually effective and should be chosen as first-line chemotherapy for inoperable tumors.
  • [MeSH-major] Extremities. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Europe. Female. Humans. Infant. Infant, Newborn. Male. Recurrence. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ramphal R, Manson D, Viero S, Zielenska M, Gerstle T, Pappo A: Retroperitoneal infantile fibrosarcoma: clinical, molecular, and therapeutic aspects of an unusual tumor. Pediatr Hematol Oncol; 2003 Dec;20(8):635-42
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal infantile fibrosarcoma: clinical, molecular, and therapeutic aspects of an unusual tumor.
  • The authors describe a patient with a large retroperitoneal infantile fibrosarcoma that responded well to preoperative chemotherapy, which subsequently facilitated the complete surgical resection of the mass.
  • The presence of the t(12;15)(p13;q25) and the fusion transcript ETV6-NTRK3 by RTPCR facilitated the diagnosis.
  • [MeSH-major] Fibrosarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14578034.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ETV6-NTRK3 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


17. Alaggio R, Ninfo V, Rosolen A, Coffin CM: Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol; 2006 Mar;30(3):388-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas in the first year of life are rare, and the most common sarcomas in infancy are embryonal rhabdomyosarcoma, Ewing sarcoma/primitive neuroectodermal tumor, congenital infantile fibrosarcoma, and primitive sarcomas such as undifferentiated sarcoma.
  • In this study, we report 6 cases of a primitive myxoid mesenchymal tumor of infancy (PMMTI), which previously may have been included under the diagnostic categories of congenital-infantile fibrosarcoma or infantile fibromatosis.
  • PMMTI occurred in 6 infants, 3 of whom had a congenital presentation of a soft tissue mass.
  • One tumor had a complex karyotypic abnormality with rearrangements involving chromosomes Y, 9, and 3.
  • Three patients had recurrences or metastasis treated with a combination of surgery and chemotherapy.
  • One patient is alive with persistent locally aggressive disease, 2 are alive with no evidence of recurrence, 1 had a recurrence treated surgically without further follow-up information, 1 patient died with persistent tumor and sepsis 6 weeks after diagnosis, and 1 patient was lost to follow-up.
  • The morphologic appearance combined with the ultrastructural features and absence of the typical gene rearrangement of congenital-infantile fibrosarcoma are unique, and we propose that PMMTI represents a new category of pediatric fibroblastic-myofibroblastic tumor.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / pathology. Nerve Sheath Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538060.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETV6-NTRK3 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


18. Kuhnen C, Harms D, Niessen KH, Diehm T, Müller KM: [Congenital pulmonary fibrosarcoma. Differential diagnosis of infantile pulmonary spindle cell tumors]. Pathologe; 2001 Mar;22(2):151-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Congenital pulmonary fibrosarcoma. Differential diagnosis of infantile pulmonary spindle cell tumors].
  • [Transliterated title] Kongenitales pulmonales Fibrosarkom. Differenzialdiagnose infantiler pulmonaler spindelzelliger Tumoren.
  • We describe a case of pulmonary spindle-cell tumor with features of infantile fibrosarcoma and discuss the differential diagnosis of spindle-cell lesions in this location.
  • Especially in congenital lesions a favorable clinical course is to be expected after complete surgical resection.
  • Additional radio- and/or chemotherapy is not recommended.
  • [MeSH-major] Fibrosarcoma / diagnosis. Lung Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Infant, Newborn. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321732.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Chastagner P: [Malignant extraconal tumors of the orbit in childhood]. Neurochirurgie; 2010 Apr-Jun;56(2-3):281-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both diagnosis and treatment must be undertaken as soon as possible.
  • Sometimes diagnosis should be clear with the association of an orbital tumor and deterioration of the general health status favoring metastatic disease.
  • Today both CT and MRI are highly valuable in assessing the diagnosis and starting the management of these tumors.
  • Biopsy is mandatory to confirm the diagnosis.
  • Among the primitive tumors, soft tissue sarcomas, especially rhabdomyosarcomas, are the most frequent.
  • The diagnosis is suggested when the onset of the disease is acute and the course is rapid.
  • Most respond to neoadjuvant chemotherapy.
  • In the event of a residual tumor, local treatment is indicated so that surgery and/or radiotherapy are used as second-line treatment.
  • It can be satisfactory (Langerhans' cell histiocytosis, lymphoma, meningioma, infantile fibrosarcoma) or poor (metastatic tumor, rhabdoid tumor).
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Exophthalmos / etiology. France. Humans. Incidence. Infant. Male. Neoplasm Metastasis. Prognosis. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20303550.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Congenital solid tumors. A thirteen-year review].
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • AIM: To contribute the experience of our institution in congenital tumors the last 13 years.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • CONCLUSIONS: Diagnosis of congenital tumors is performed earlier in recent years due to the wide use of prenatal ultrasound.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • We ought to pass this message on to our colleagues in prenatal diagnosis, so parents get reliable information.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Minard-Colin V, Orbach D, Martelli H, Bodemer C, Oberlin O: [Soft tissue tumors in neonates]. Arch Pediatr; 2009 Jul;16(7):1039-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue tumors in neonates].
  • Soft tissue tumors account for approximately 25% of neonatal tumors and are most often benign (more than 2/3 of cases).
  • Vascular tumors are the most frequent benign tumors and infantile hemangioma accounts for 32% of these tumors, affecting 1 out of 200 children at birth.
  • Malignant soft tissue tumors are, after neuroblastoma, the second cause of cancer in neonates.
  • Infantile fibrosarcoma (IF) is a rare tumor that most often affects the extremities of children aged 4 years or younger.
  • Chemotherapy is indicated when initial surgical removal cannot be accomplished without unacceptable morbidity.
  • Treatment is based on age-adapted chemotherapy and surgery.
  • [MeSH-major] Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Fibrosarcoma / congenital. Fibrosarcoma / diagnosis. Fibrosarcoma / genetics. Fibrosarcoma / therapy. Gene Fusion / genetics. Gene Rearrangement / genetics. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangioma / congenital. Hemangioma / diagnosis. Hemangioma / therapy. Humans. Infant, Newborn. Prognosis. Proto-Oncogene Proteins c-ets / genetics. Receptor, trkC / genetics. Repressor Proteins / genetics. Rhabdomyosarcoma / congenital. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398311.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  • [Number-of-references] 37
  •  go-up   go-down


22. Durin L, Jeanne-Pasquier C, Bailleul P, Eboué C, Aicardi S, Herlicoviez M, Dreyfus M: Prenatal diagnosis of a fibrosarcoma of the thigh: a case report. Fetal Diagn Ther; 2006;21(6):481-4
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal diagnosis of a fibrosarcoma of the thigh: a case report.
  • We report a rare case of fibrosarcoma of the thigh suspected prenatally.
  • At 27 weeks of gestation a voluminous, vascularised mass was discovered at ultrasound on the foetus' left leg, suggestive of haemangioma or a fibrosarcoma.
  • Postnatal ultrasound examination was comparable to that carried out prenatally; pathological examination of the mass biopsied and immunohistochemical investigation provided a diagnosis of congenital fibrosarcoma.
  • After neoadjuvant chemotherapy and surgery the infant is now in complete remission without amputation.
  • [MeSH-major] Fibrosarcoma / ultrasonography. Thigh. Ultrasonography, Prenatal
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968999.001).
  • [ISSN] 1015-3837
  • [Journal-full-title] Fetal diagnosis and therapy
  • [ISO-abbreviation] Fetal. Diagn. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Cytogenetic discoveries of balanced translocations in soft tissue tumors have opened the way to molecular genetic definition of these translocations as gene fusions from the late 1980s.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • Demonstration of sarcoma translocations and their fusion by different assays is well established; use of in situ hybridization is limited by availability of specific probes.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
  • Activating mutations in two related receptor tyrosine kinases (RTKs), KIT, and platelet-derived growth factor receptor alpha (PDGFRA) is central to the pathogenesis of gastrointestinal stromal tumors (GISTs), and countering the mutational activation by specific tyrosine kinase inhibitors, such as Imatinib mesylate, is now standard treatment for metastatic GISTs.
  • Mutation type influences therapy responsiveness, but fortunately very few GISTs carry primarily Imatinib-resistant mutations.
  • Secondary drug resistance acquired during Imatinib treatment based on new, Imatinib-resistant mutations is a major problem limiting treatment success.
  • Schwannoma types may differ in their pathogenesis: gastrointestinal schwannomas lack NF2 changes suggesting a different pathogenesis.
  • Specific viral sequences of human herpesvirus 8 (HHV8) are diagnostic markers for Kaposi sarcoma (KS), and are absent in angiosarcoma.
  • [MeSH-major] Genetic Testing. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


24. Cecchetto G, Carli M, Alaggio R, Dall'Igna P, Bisogno G, Scarzello G, Zanetti I, Durante G, Inserra A, Siracusa F, Guglielmi M, Italian Cooperative Group: Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979-1995). J Surg Oncol; 2001 Dec;78(4):225-31
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979-1995).
  • BACKGROUND AND OBJECTIVES: Fibrosarcoma is a rare soft tissue sarcoma (STS) that has two peaks of incidence in pediatric patients: one in infants and young children (infantile fibrosarcoma), another in older children ("adult type" fibrosarcoma).
  • The purpose of this study was to describe the clinical features and the treatment results in patients affected by fibrosarcoma enrolled in two consecutive studies run by the STS-Italian Cooperative Group (ICG) between 1979 and 1995.
  • The cut-off point between the two forms was considered the age of 2 years: 14 patients were affected by infantile and 11 by adult type of fibrosarcoma.
  • The therapeutic guidelines were not strict and not different for the two forms: patients with initial macroscopic excision (Gr I-II) were given IVA or VAC; Gr III had VAC or VAIA and subsequent excision, if feasible.
  • Radiation therapy (RT) was delivered in patients > 3 years with microscopic (42 Gy) and macroscopic (54 Gy) residuals.
  • One Gr III patient was lost at follow up, 2 years from diagnosis.
  • CONCLUSIONS: The complete excision at diagnosis was the treatment of choice and was related to the best outcome.
  • Microscopical residuals were difficult to treat with chemo-radiotherapy in both forms of fibrosarcoma.
  • Neoadjuvant chemotherapy (CT) obtained a partial remission (PR) only in three of eight cases, while no conclusions concerning the efficacy of CT for infantile forms are possible.
  • Patients < 2 years had a better outcome than the older ones: most of them had a tumor on extremities which was excised at diagnosis.
  • [MeSH-major] Fibrosarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Radiotherapy Dosage. Sarcoma / radiotherapy. Sarcoma / surgery. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745814.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Tuveson DA, Fletcher JA: Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol; 2001 Jul;13(4):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transduction pathways in sarcoma as targets for therapeutic intervention.
  • Investigations into the molecular alterations in sarcomas have made substantial progress during the past decade.
  • Classical linkage analysis and the direct sequencing of chromosomal translocation fusions have identified candidate genes in many different sarcomas.
  • A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies.
  • This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
  • [MeSH-major] Signal Transduction. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Protein-Tyrosine Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11429482.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 80
  •  go-up   go-down


26. Hadley GP, Govender D, Landers G: Malignant solid tumours in neonates: an African perspective. Pediatr Surg Int; 2002 Dec;18(8):653-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma (NB) was the commonest tumour seen (11), but the soft-tissue sarcomas were the dominant group (14).
  • Chemotherapy, despite appropriate dose reduction, had significant morbidity and mortality.
  • Whilst the outcome for congenital fibrosarcoma was good (6/7, 86%), there were no survivors amongst 5 patients with rhabdomyosarcoma.
  • Stage I disease was associated with a good prognosis, whilst stage IV disease was uniformly fatal.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Neoplasm Staging. South Africa / epidemiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12598957.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Grohn ML, Borzi P, Mackay A, Suppiah R: Management of extensive congenital fibrosarcoma with preoperative chemotherapy. ANZ J Surg; 2004 Oct;74(10):919-21
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of extensive congenital fibrosarcoma with preoperative chemotherapy.
  • [MeSH-major] Fibrosarcoma / congenital. Fibrosarcoma / drug therapy. Thoracic Neoplasms / congenital. Thoracic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15456453.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Spicer RD: Right foot congenital infantile fibrosarcoma treated only with chemotherapy. Pediatr Blood Cancer; 2010 Oct;55(4):770; author reply 771
MedlinePlus Health Information. consumer health - Foot Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right foot congenital infantile fibrosarcoma treated only with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / congenital. Fibrosarcoma / drug therapy. Foot / pathology. Soft Tissue Neoplasms / congenital. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2010 Apr;54(4):618-20 [19998472.001]
  • (PMID = 20533521.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


29. Surico G, Muggeo P, Daniele RM, Novielli C, Rigillo N, Minervini C: Chemotherapy alone for the treatment of congenital fibrosarcoma: is surgery always needed? Med Pediatr Oncol; 2003 Apr;40(4):268-70
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone for the treatment of congenital fibrosarcoma: is surgery always needed?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / congenital. Fibrosarcoma / drug therapy. Hand / pathology
  • [MeSH-minor] Dactinomycin / administration & dosage. Humans. Ifosfamide / administration & dosage. Infant. Magnetic Resonance Imaging. Male. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555264.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement